AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM” or the 'Company”) today announced milestones in the expected timeline for the ...

MIAMI, FLORIDA (Jan. 9, 2026) – A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, ...

In this substudy of the phase 3 RAMPART trial, researchers compared quality-of-life measures among patients who received either active monitoring or durvalumab plus tremelimumab for resected RCC.

OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM) (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 ...

Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, ...

Patients with resected renal cell carcinoma (RCC) receiving adjuvant durvalumab (Imfinzi) plus tremelimumab-actl (Imjudo) experienced early reductions in patient-reported quality of life (QoL), ...

Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug ...

Thus, the phase 3 TOPAZ-1 trial (NCT03875235) made big news in 2021 when it met its primary overall survival (OS) end point in an interim analysis. Among patients with newly diagnosed advanced BTC, ...

OCALA, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a mid-year update from the ongoing Phase 2 clinical ...